37 / 41
Volume 6, Issue 4 (Suppl)
Clin Pharmacol Biopharm, an open access journal
ISSN: 2167-065X
Page 91
Euro Biopharma & Ethnopharmacology 2017
November 09-11, 2017
&
6
th
International Conference and Exhibition on
November 09-11, 2017 Vienna, Austria
4
th
EUROPEAN BIOPHARMA CONGRESS
PHARMACOLOGY AND ETHNOPHARMACOLOGY
Joint Event
An overexploitation approach for cell culture based modular bioprocessing
Ravindra Patel
OmniBRx Biotechnologies Pvt. Ltd, India
I
n the battle of controlling healthcare costs, the high cost pharmaceuticals, especially biologics has become an important
issue. Successful production planning requires consideration of cost factors such as manufacturing cost, capital investment
to build new facilities or to retrofit existing ones, as well as the inventory costs. The cost attributed to the opportunity lost in
selling the product or failure to meet market demand is also considered as the inventory cost. Any unplanned downtime could
severely affect the customer service level, if facility utilization is too high. Underutilization of manufacturing facilities conversely
suggests a misplaced investment in capacity. The overexploitation approach is designed to mitigate the above described facility
constrains due to its power of combining the benefits of perfusion & fed batch processing mode with adequate elimination of
facility constrains of fed-batch bioprocessing. The key factors considered are: 1. Adapting to modular single use technologies
for facility design. 2. Smallest mall footprint for upstream processing saves initial investment, significantly. 3. Multiproduct
facilities to be designed capable of offering production output in kilograms per month. 4. Completely avoiding the use of
conventional Stainless steel bioreactors. 5. Culture revived from single low-passage cell bank can be expanded for several
months without compromising the product quality. With continuous processing advantage while adapting an overexploitation
approach, the cultured cells can be processed up to 60 passages, typically.
Ravindra.Patel@omnibrx.comClin Pharmacol Biopharm 2017, 6:4(Suppl)
DOI: 10.4172/2167-065X-C1-026